GLP‑1 Coverage Is Slipping

Coverage for Wegovy and Zepbound has dropped fast, leaving millions of Americans to pay cash or stop treatment. (npr.org) NPR reported on April 22 that about 12 million people lost insurance coverage for Zepbound over the past year, and another 12 million lost coverage for Wegovy, citing data from IQVIA. IQVIA said the pullback came as employers and health plans tightened formularies and added restrictions to obesity-drug benefits. (npr.org) (iqvia.com) These drugs are glucagon-like peptide-1 medicines, a class that helps people feel fuller and eat less; Zepbound also acts on a second hormone target called glucose-dependent insulinotropic polypeptide. The Food and Drug Administration approved Zepbound for chronic weight management in November 2023, and Wegovy is approved to reduce excess weight long term in adults with obesity or overweight plus a related condition. (fda.gov) (accessdata.fda.gov) The coverage retreat is colliding with high sticker prices and long-term use. IQVIA said direct-to-patient programs have lowered cash prices from more than $1,000 a month to roughly $299 to $499, but those programs still shift costs to patients who no longer have insurance coverage. (iqvia.com) (wegovy.com) (zepbound.lilly.com) Drugmakers have been moving to meet that cash market. Novo Nordisk said on February 24 it would cut the U.S. list price of Wegovy, and on March 31 it launched a subscription program; Eli Lilly says eligible patients whose commercial insurance does not cover Zepbound can get the drug starting at $299 for a one-month prescription through its savings offer. (novonordisk-us.com) (zepbound.lilly.com) Insurers and employers have been warning for months that broad coverage would be expensive. KFF reported in October 2025 that employers were considering scaling back coverage or adding stricter requirements for glucagon-like peptide-1 drugs used for weight loss because of cost. (kff.org) Public coverage remains patchy too. KFF said in January 2026 that Medicare still does not cover glucagon-like peptide-1 drugs when they are prescribed for obesity alone, and only 13 state Medicaid fee-for-service programs covered these drugs for obesity treatment as of January 2026. (kff.org) (cms.gov) That leaves access increasingly split by benefit design, employer choice, and a patient’s ability to keep paying month after month. The drugs are still on the market, but coverage is deciding who can stay on them. (npr.org) (iqvia.com)